Dan Theodorescu, MD, PhD
Distinguished Professor, Surgery-Transplant

Professor Surgery-Urology
Director, University of Colorado Comprehensive Cancer Center
Co-Editor in Chief, Bladder Cancer
Print Profile
Email Profile
Photo

Gender: Male
Languages: English
Department, Section/Division: Surgery-Transplant
Pharmacology

Practice Locations

Hospital Affiliation
  • University of Colorado Hospital
Center Affiliations

Specialty Information

Specialties
  • Urology, Board Certification (1999,2007)
Clinical Interest for Patients
I have suspended my clinical practice in order to focus on research and administration of the cancer center

Information for Referring Providers

Clinical Interests for Referring Providers
I have suspended my clinical practice in order to focus on research and administration of the cancer center

Research Interest for Referring Providers
Working on a disease that has seen few advances in the last 30 years, Theodorescu has emerged as a leading translational bladder cancer researcher. Theodorescu is known for his work on the molecular mechanisms underlying bladder cancer and tools that determine drug response as well as discovery of new drugs for several cancer types. Examples include discovery of genes that regulate tumor growth and metastasis (RhoGDI2, CD24, AGL, GON4L) in bladder and other cancers and novel biomarkers (DNA/NGS, RNA and proteomic) and concepts for precision therapeutic approaches such as the COXEN principle, that are currently being tested in national (SWOG) clinical trials. He led the discovery and development of a “first in class” RalGTPase inhibitor as a new therapeutic in several human cancer types which is now in commercial development. Recent efforts in our lab have focused on understanding the biology of Telomerase reverse transcriptase (TERT) and using that knowledge to develop novel inhibitors to this critical protein in cancer. Finally, active efforts are currently aimed at identifying immune system agonists or antagonists that modulate tumor behavior in vivo as well as the identification of novel combination therapies that enhance the effectiveness of checkpoint and other immunotherapy.
Contact Us
In An Emergency: Please Dial 911

University of Colorado Medicine (CU Medicine)
http://www.CUmedicine.us/contact-us
Refer a Patient: 720-848-2828
Billing Questions: 303-493-7000

Twitter   Facebook
CU Doctors